Efficacy and safety of epirubicin and etoposide combination chemotherapy in advanced hepatocellular carcinoma: A retrospective analysis

Lee, Jae‐Lyun; Ryu, Min‐Hee; Chang, Heung Moon; Kim, Tae−Won; Lee, Sung S.; Sym, Sun Jin; Kim, Min K.; Kim, Kang M.; Lee, Jung S; Kang, Yoon‐Koo

doi:10.1111/j.1440-1746.2007.05213.x

Cited by 7 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This data supports the possible biological difference between patients with and without viral infection 19 . This finding is consistent with previous study with chemotherapy indicating that HCC correlate with infection hepatitis B have a greater aggressiveness than non-virus-related tumors 20 . HBV related tumors have different genetic mutations with greater chromosome instability respect other etiologies and have higher prevalence of loss of heterozygosity 21 .…”

Section: Discussionsupporting

confidence: 93%

Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study

Casadei-Gardini

Foca

Scartozzi

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Preliminary studies suggest that capecitabine may be safe and effective in HCC patients. The aim of this study was to retrospectively evaluate the safety and efficacy of metronomic capecitabine as second-line treatment. This multicentric study retrospectively analyzed data of HCC patients unresponsive or intolerant to sorafenib treatment with metronomic capecitabine or best supportive care (BSC).Median progression free survival was 3.1 months in patients treated with capecitabine (95%CI: 2.7–3.5). Median overall survival was 12.0 months (95% CI: 10.7–15.8) in patients receiving capecitabine, while 9.0 months (95% CI: 6.5–13.9) in patients receiving BSC. The result of univariate unweighted Cox regression model shows a 46% reduction in death risk for patients on capecitabine (95%CI: 0.357–0.829; p =0.005) compared to patients receiving BSC alone. After weighting for potential confounders, death risk remained essentially unaltered (45%; 95%CI: 0.354–0.883; p = 0.013). Metronomic capecitabine seems a safe second-line treatment for HCC patients in terms of management of adverse events, showing a potential anti-tumour activity which needs further evaluation in phase III studies.

show abstract

Section: Discussionsupporting

confidence: 93%

Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study

Casadei-Gardini

Foca

Scartozzi

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“… 33 Also, the efficacy of epirubicin and cisplatin in TACE has been chronicled. 34 – 37 We have previously reported the efficacy and safety of the TAC-ECF in large, extensive HCC with PVTT, which showed a 5.2 months survival benefit in comparison with conservative management 38 and the efficacy of TAC-ECF combined with PEI in unresectable HCC, which showed a survival benefit of 3 months compared to TACE using DOX. 22 However, there has been no report on the long-term follow-up results of this combination regimen versus conventional TACE using DOX for unresectable HCC with PVTT.…”

Section: Discussionmentioning

confidence: 99%

Transarterial infusion of epirubicin and cisplatin combined with systemic infusion of 5-fluorouracil versus transarterial chemoembolization using doxorubicin for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective analysis

Lee

Han

et al. 2017

Ther Adv Med Oncol

View full text Add to dashboard Cite

Background:More than one-third of hepatocellular carcinoma (HCC) patients are diagnosed at advanced stage with portal vein tumor thrombosis (PVTT) or extrahepatic metastasis. However, the outcomes of current therapeutic approaches are unsatisfactory. As a novel therapeutic strategy for unresectable HCC with PVTT, we analyzed the outcomes of transarterial infusion of epirubicin and cisplatin combined with systemic infusion of 5-fluorouracil (TAC-ECF) and compared its therapeutic effects and toxicity with transarterial chemoembolization (TACE) using doxorubicin (DOX).Methods:A total of 540 consecutive HCC patients who received TACE at the Catholic Medical Center between January 2007 and November 2013 were enrolled. Of these patients, we retrospectively analyzed 129 Barcelona clinic liver cancer stage C HCC patients with PVTT who received either TAC-ECF or TACE using DOX.Results:The objective tumor response rate was higher in the TAC-ECF group, with 31.3% objective response rate after TAC-ECF compared to 10% after DOX treatment (p = 0.004). Median follow-up period was 7 months (range, 1–57 months). The overall survival rate was also significantly higher in the TAC-ECF group compared to the DOX group (median 9.3 versus 4.6 months, p < 0.0001). Multivariate analysis revealed that TAC-ECF and extrahepatic metastasis were independent predictive factors for overall survival (p < 0.0001 and p = 0.002 respectively). No serious adverse effects developed in both groups.Conclusions:TAC-ECF therapy was tolerable and showed higher overall survival rate and tumor response compared to the conventional TACE DOX in advanced stage HCC patients with PVTT. Therefore, TAC-ECF may be considered as an effective treatment option for patients with unresectable HCC.

show abstract

“…In the current issue of the Journal, Lee et al . report a study in which the efficacy and safety of epirubicin and etoposide combination chemotherapy were assessed in patients with advanced HCC 8 . In spite of previous promising results, 9 they did not find promising antitumor activity of the epirubicin and etoposide combination regimen in advanced HCC.…”

mentioning

confidence: 98%

Chemotherapy for advanced hepatocellular carcinoma

Han

Park

2008

J of Gastro and Hepatol

View full text Add to dashboard Cite

Efficacy and safety of epirubicin and etoposide combination chemotherapy in advanced hepatocellular carcinoma: A retrospective analysis

Abstract: Treatment with EE showed minimal antitumor activity with acceptable toxicity in HBV-associated AHCC, especially in patients pretreated with TACE.

Cited by 7 publications

References 28 publications

Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study

Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study

Transarterial infusion of epirubicin and cisplatin combined with systemic infusion of 5-fluorouracil versus transarterial chemoembolization using doxorubicin for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective analysis

Chemotherapy for advanced hepatocellular carcinoma

Contact Info

Product

Resources

About